Clinical reversal of multidrug resistance.
Sikic
B I
BI
Stanford University Medical Center, CA 94305.
Fisher
G A
GA
Lum
B L
BL
Brophy
N A
NA
Yahanda
A M
AM
Adler
K M
KM
Halsey
J
J
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001693:Biological Transport, Active / Q000187:drug effects; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018432:Drug Resistance, Multiple; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017239:Paclitaxel / Q000494:pharmacology / Q000627:therapeutic use; D004364:Pharmaceutical Preparations / Q000378:metabolism; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D004364:Pharmaceutical Preparations; D005047:Etoposide; D016572:Cyclosporine; D014700:Verapamil; D017239:Paclitaxel